Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells

Sugiyama, Kanako; Shirai, Ryo; Mukae, Hiroshi; Ishimoto, Hiroshi; Nagata, Towako; Sakamoto, Noriho; Ishii, Hiroshi; Nakayama, Seiko; Yanagihara, Katsunori; Mizuta, Yohei; Kohno, Shigeru

doi:10.1111/j.1365-2249.2007.03299.x

Cited by 88 publications

(97 citation statements)

References 44 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Azithromycin and clarithromycin significantly upregulated the expression of CD80, a costimulatory molecule for T-cell activation, from murine bone marrow-derived DCs (270). Azithromycin, but not clarithromycin, increased the production of IL-10, and clarithromycin, but not azithromycin, inhibited the production of IL-6 by DCs.…”

Section: Effects On Inflammationmentioning

confidence: 99%

Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications

2010

View full text Add to dashboard Cite

SUMMARY Macrolides have diverse biological activities and an ability to modulate inflammation and immunity in eukaryotes without affecting homeostatic immunity. These properties have led to their long-term use in treating neutrophil-dominated inflammation in diffuse panbronchiolitis, bronchiectasis, rhinosinusitis, and cystic fibrosis. These immunomodulatory activities appear to be polymodal, but evidence suggests that many of these effects are due to inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation and nuclear factor kappa B (NF-κB) activation. Macrolides accumulate within cells, suggesting that they may associate with receptors or carriers responsible for the regulation of cell cycle and immunity. A concern is that long-term use of macrolides increases the emergence of antimicrobial resistance. Nonantimicrobial macrolides are now in development as potential immunomodulatory therapies.

show abstract

Section: Effects On Inflammationmentioning

confidence: 99%

Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications

2010

View full text Add to dashboard Cite

show abstract

“…Anti-inflammatory effects (10,11), inhibitory effects on respiratory secretions (12) and modulation of bacterial functions (13) have been reported for macrolide antibiotics, in addition to their antibiotic effects, and the clinical effects of these drugs as immunomodulatory agents have been observed, especially in patients with DPB (14,15). In addition to anti-inflammatory effects, Sugiyama et al (16) reported that AZM and CAM may have had different pharmacological effects due to their different regulatory effects on cytokine production in pneumocyte-like cells. Moreover, AZM was reported to have a stronger modulatory effect on bacterial functions than CAM, especially the thinning effect on bacterial biofilms and suppressive effect on the bacterial proliferation of Pseudomonas aeruginosa in vitro (17,18).…”

Section: Discussionmentioning

confidence: 99%

A Case of Good Syndrome with Pulmonary Lesions Similar to Diffuse Panbronchiolitis

et al. 2012

View full text Add to dashboard Cite

We herein present a case of Good syndrome complicated by diffuse pulmonary lesions similar to diffuse panbronchiolitis (DPB). A 45-year-old Japanese man was referred to our department due to recurrent lower respiratory tract infections that had started and ameliorated nine months after thymectomy for pure red cell aplasia and myasthenia gravis. Diffuse centrilobular opacities on chest computed tomography and positivity for HLA-B54 were consistent with DPB. Additionally, hypogammaglobulinemia and a marked decrease of Blymphocytes were observed, and therefore Good syndrome was considered. Combination therapy with azithromycin and clarithromycin alleviated the patient's respiratory symptoms and reduced the exacerbation of chronic bronchitis.

show abstract

“…Clarithromycin affects cytokine production by dendritic cells and T cells by inhibiting IL-2 and IL-6 production, suppressing B cell activation and improving the condition of patients with lung disease (Sugiyama et al, 2007). Furthermore, it increases production of IL-10, which inhibits the production of pro-inflammatory cytokines such as IL-2, IL-8, and TNF-a.…”

Section: Discussionmentioning

confidence: 99%

WBC count and functional changes induced by co-administration of clofazimine and clarithromycin, in single and multiple doses, in Wistar rats

Paina

Miranda

Tavares

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Clofazimine and clarithromycin are used to treat leprosy and infections caused by Mycobacterium avium complex. Little data on the toxicity of co-administration of these two drugs are available. Here we evaluated the potential adverse effects of polytherapy with these two drugs in male Wistar rats by determining WBCs counts and other blood cell counts, neutrophilic phagocytosis, and burst oxidative, by flow cytometry. We observed an increase in WBCs, in multiple-dose regimens, and in polymorphonuclear cells, in both single-clarithromycin only and multiple dose regimens. We also observed a reduction in mononuclear cell counts in single and multiple doses. The drugs seem to reverse the mononuclear and polymorphonuclear cell ratio. An increase in oxidative burst was observed in animals treated with the drugs administered either individually or combined. In conclusion, clofazimine and clarithromycin change WBCs counts. Our results may contribute for a better understanding of the mechanisms related to the effects of co-administrating the two drugs.Uniterms: Clofazimine/adverse effects/experimental study. Clarithromycin/adverse effects/experimental study. Leprosy/treatment. Mycobacterium avium/infections/treatment. Leukocytes. Phagocytosis. Oxidative burst.Clofazimina e laritromicina são utilizadas no tratamento da hanseníase e em infecções causadas pelo complexo Mycobacterium avium. Devido à escassez de dados sobre a toxicidade de esquemas terapêuticos que associam estes fármacos, este estudo teve por objetivo avaliar os efeitos adversos desta terapia, em ratos machos Wistar, por meio da determinação da contagem global e específica de leucócitos e ensaios de fagocitose e burst oxidativo de neutrófilos por citometria de fluxo. Houve aumento do número de leucócitos (dose múltipla) e de células polimorfonucleares (doses única e múltipla) nos grupos tratados com claritromicina em monoterapia ou associada à clofazimina e redução das células mononucleares, em doses única e múltipla, nos mesmos grupos. Os fármacos parecem inverter a proporção entre células mono e polimorfonucleares. Observou-se aumento do burst oxidativo nos animais tratados com os fármacos isolados ou associados. Concluindo, clofazimina e claritromicina provocam alterações leucocitárias e os resultados podem contribuir para melhor entendimento dos mecanismos relacionados aos efeitos da administração dos fármacos em associação.Unitermos: Clofazimina/efeitos adversos/estudo experimental. Claritromicina/efeitos adversos/ estudo experimental. Hanseníase/tratamento. Mycobacterium avium/infecções/tratamento. Leucócitos. Fagocitose. Burst oxidativo.

show abstract

Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells

Cited by 88 publications

References 44 publications

Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications

Mechanisms of Action and Clinical Application of Macrolides as Immunomodulatory Medications

A Case of Good Syndrome with Pulmonary Lesions Similar to Diffuse Panbronchiolitis

WBC count and functional changes induced by co-administration of clofazimine and clarithromycin, in single and multiple doses, in Wistar rats

Contact Info

Product

Resources

About